Huakwang Biotech's Continuous Glucose Monitoring System (CGM) Receives EU MDR Certification

Disclosure Date: July 13, 2026 Statement Date: July 12, 2026 Statement Time: 16:48:35 Company Code: 4737 Company Name: Huakwang Biotech Co., Ltd. Subject: Announcement of EU MDR Certification for the Company's Continuous Glucose Monitoring System (CGM) Applicable Clause: Article 51 Event Date: July 10, 2026

Details: 1. Event Date: July 10, 2026 2. Company Name: Huakwang Biotechnology Co., Ltd. 3. Relationship to Company:本公司 (the Company itself) 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: The company's self-developed and manufactured Continuous Glucose Monitoring System (CGM) has successfully passed the certification under the European Union's Medical Device Regulation (MDR), Certificate Number MDR 832658. 6. Response Measures: Issuance of this announcement. 7. Other Matters to be Disclosed: The certified product, the Continuous Glucose Monitoring System (CGM), is intended for diabetic patients aged 18 years and above, designed to detect glucose trends and assist in blood glucose management. The system is designed to replace finger-prick blood glucose testing as a basis for diabetes treatment decisions, and can also assist in detecting hyperglycemic and hypoglycemic events, serving as a reference for acute and long-term treatment adjustments. Interpretation of results should be based on both glucose trend data and continuous readings.